Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer

blonca9
Aug 7, 2024
1 min read

David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer medicines, and how he thinks about deals going forward.

Recent Posts

See All

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy

ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy

Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight